<DOC>
	<DOCNO>NCT02287415</DOCNO>
	<brief_summary>Multiple-dose , open-label , single-period study consist three consecutive phase</brief_summary>
	<brief_title>The Effect BIA 2-093 Steady-state Pharmacodynamic Pharmacokinetic Profiles Warfarin</brief_title>
	<detailed_description>Multiple-dose , open-label , single-period study consist three consecutive phase : Phase A - run-in warfarin dose-finding phase Phase B - warfarin pharmacokinetics ( PK ) international normalise ratio ( INR ) profile Phase C - warfarin alone individualised dos</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Male female subject age 18 45 year , inclusive Subjects body mass index ( BMI ) 19 28 kg/m2 , inclusive Subjects healthy determine prestudy medical history , physical examination , neurological examination , 12lead ECG Subjects clinical laboratory test clinically acceptable Subjects negative HBs Ag , antiHCV Ab antiHIV1 HIV2 Ab test screen Subjects negative alcohol drug abuse screen Subjects nonsmoker smoke less 10 cigarette equivalent per day Subjects able willing give write informed consent In case female volunteer , subject childbearing potential reason surgery , childbearing potential , use one follow method contraception : doublebarrier intrauterine device In case female volunteer , subject negative pregnancy test screening Subjects conform inclusion criterion Subjects clinically relevant history presence respiratory gastrointestinal , renal , hepatic , haematological , lymphatic , neurological cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological dermatological , endocrine , connective tissue diseases disorder Subjects current haemostatic disorder personal family history disorder Subjects personal family history bleed complication surgery tooth extraction , nose gingival bleeding , haemorrhagic diathesis . Subjects profession activity imply special risk trauma Subjects abnormality coagulation status ( aPTT prothrombin INR ) Subjects clinically relevant surgical history Subjects clinically relevant family history Subjects history relevant atopy Subjects history relevant drug hypersensitivity Subjects history alcoholism drug abuse Subjects consume 14 unit alcohol week Subjects significant infection know inflammatory process screen and/or admission Subjects acute gastrointestinal symptom time screen and/or admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) Subjects use prescription drug within 2 week prior admission Phase A Subjects use investigational drug and/or participate clinical trial within 2 month prior admission Phase A Subjects previously receive BIA 2093 Subjects donate and/or receive blood blood product within previous 2 month prior admission Phase A Subjects vegetarian , vegan and/or medical dietary restriction Subjects could communicate reliably investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>